Marina Biotech is a leading clinical-stage RNA therapeutics company focused on research and development of novel therapeutics for significant unmet medical needs based on the Nobel Prize winning discovery of RNA interference. We will continue to develop and acquire multiple drug discovery and delivery technologies necessary to broadly capitalize on the advantages of an RNAi-based therapeutic across a variety of human disease. Learn More
Stock Quote |
Featured News
- 05/10/12Marina Biotech Receives Three Notices of Allowances From the USPTO and an Intent to Grant Notice From the European Patent Office
- 05/08/12Marina Biotech Announces Worldwide Exclusive Licensing Agreement With Monsanto
- 04/19/12Marina Biotech Regains Intellectual Property Rights to Its tkRNAi(TM) Technology for Agriculture and Veterinary Uses
- 04/03/12Marina Biotech Completes Dosing of Second Cohort in the Phase 1b START-FAP Clinical Trial of CEQ508
Contact Information
| Primary IR Contact |
| Philip Ranker Interim Chief Financial Officer Phone: 425-908-3600 E-mail: ir@marinabio.com |
| Transfer Agent |
| American Stock Transfer & Trust Company 59 Maiden Lane New York, NY 10038 Phone: 877-777-0800 Corporate Website: http://www.amstock.com |
| Legal |
| Pryor Cashman Sherman & Flynn LLP 410 Park Avenue New York, NY 10022 Phone: (212) 421-4100 Corporate Website: http://www.pryorcashman.com |
| Accountants |
| KPMG 3100 Two Union Square 801 Second Avenue Seattle, WA 98104 Phone: 206-292-1500 Corporate Website: http://www.kpmgcampus.com |
 |
 Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |